JPRN-UMIN000004514已完成未知
A phase II study of PAD therapy (bortezomib, doxorubicin, and dexamethasone) for relapsed or refractory multiple myeloma. - PAD therapy for advanced multiple myeloma
Department of Hematology and Respiratory Medicine, Kochi University0 个研究点目标入组 20 人开始时间: 2010年11月9日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who have a serious active infection 2. Patients who have complication of active double cancer 3. Women who are or may be pregnant or are nursing 4. Patients with grade 2 or severer peripheral neuropathy or peripheral neurogenic pain (CTCAE v4.0) 5. Patient diagnosed with interstitial pneumonia in high resolution CT, and judged to improper to administer bortezomib 6. Other patients who are unfit for enrollment in the study
研究者
相似试验
已完成
2 期
A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone) induction therapy in transplant-eligible patients with untreated multiple myeloma (MM), stratified for markers of bortezomib resistance.Cancer - MyelomaMultiple MyelomaACTRN12609000296235Janssen-Cilag Pty Ltd107
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDRewly diagnosed Waldenstrom's macroglobulinemia (WM)MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-NLEuropean Myeloma Network90
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Networkimmunocytomalymphoplasmacytic lymphomaWaldenstroms Macroglobulinemia10018865NL-OMON30654Academisch Medisch Centrum5
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - protocole BDRMacroglobulinémie de Waldenström au moment de l’initiation du traitement de 1e ligne.EUCTR2006-003563-31-FRCentre Hospitalier de Lens61